-----But the year could prove most critical for money-losing Dendreon. If Provenge sales stabilize, expense cuts could help the company survive. However, if sales continue to shift away from Provenge to Zytiga and Xtandi, then Dendreon's survival may be in question.----
I believe the warning is out with sales slumping..
the last time you guys picked on him the stock dropped $1+ the quarter before last
bad karma old man
convertible debt,cash burn,cogs etc. you could hand this company 10 billion dollars and they'd lose it.
enough said..nobody will buy this turd over 1.99